![](https://endpts.com/wp-content/uploads/2023/09/Peter-Salzmann.jpg)
Pete Salzmann, Immunovant CEO
Immunovant takes on argenx, J&J with plans to test FcRn inhibitor in multiple parallel trials after PhI win
Immunovant is gearing up to start a slate of mid-stage as well as pivotal trials for its follow-on autoimmune drug, IMVT-1402, after confirming what it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.